In subjects with latent MM who were at risk of evolution to active myeloma, therapy with IL-1 inhibitors reduced the myeloma growth and CRP concentrations in those who responded, with a chronic disease state and an improved PFS [37]. Here, IL1A is linked to plasma cell myeloma.